

Nick Willcox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8320768/publications.pdf>

Version: 2024-02-01

32
papers

2,847
citations

279701

23
h-index

414303

32
g-index

33
all docs

33
docs citations

33
times ranked

2801
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. <i>Journal of Experimental Medicine</i> , 2010, 207, 299-308.	4.2	593
2	Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1. <i>PLoS Medicine</i> , 2006, 3, e289.	3.9	364
3	Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. <i>Annals of Neurology</i> , 2005, 57, 444-448.	2.8	216
4	Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4389-4397.	1.8	176
5	Somatic Hypermutation and Selection of B Cells in Thymic Germinal Centers Responding to Acetylcholine Receptor in Myasthenia Gravis. <i>Journal of Immunology</i> , 2001, 167, 1935-1944.	0.4	167
6	An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. <i>Nature</i> , 2007, 448, 934-937.	13.7	167
7	Myasthenia gravis. <i>Current Opinion in Immunology</i> , 1993, 5, 910-917.	2.4	117
8	Myasthenia Gravis Thymus. <i>American Journal of Pathology</i> , 2007, 171, 893-905.	1.9	113
9	Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. <i>Journal of Neuroimmunology</i> , 2002, 125, 185-197.	1.1	96
10	Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. <i>Immunological Reviews</i> , 1998, 164, 157-168.	2.8	94
11	<i>Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 84-92.	1.8	93
12	The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond. <i>Journal of Thoracic Oncology</i> , 2010, 5, S266-S272.	0.5	91
13	<i>Autoimmunizing Mechanisms in Thymoma and Thymus</i>*. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 163-173.	1.8	68
14	A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. <i>Human Immunology</i> , 1999, 60, 909-917.	1.2	64
15	Early-onset myasthenia gravis: A recurring T-cell epitope in the adult-specific acetylcholine receptor ? subunit presented by the susceptibility allele HLA-DR52a. <i>Annals of Neurology</i> , 1999, 45, 224-231.	2.8	56
16	Thymus and autoimmunity. <i>Seminars in Immunopathology</i> , 2021, 43, 45-64.	2.8	47
17	Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen Transcripts in Their Tumors. <i>Journal of Immunology</i> , 2014, 193, 3880-3890.	0.4	46
18	Antibodies to Acetylcholine Receptor in Parous Women with Myasthenia: Evidence for Immunization by Fetal Antigen. <i>Laboratory Investigation</i> , 2002, 82, 1407-1417.	1.7	45

#	ARTICLE	IF	CITATIONS
19	Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis Patients. <i>Journal of Immunology</i> , 2014, 193, 1055-1063.	0.4	45
20	Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. <i>Human Immunology</i> , 2013, 74, 1184-1193.	1.2	41
21	The ageing and myasthenic thymus: A morphometric study validating a standard procedure in the histological workup of thymic specimens. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 64-73.	1.1	39
22	True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. <i>Journal of Neuroimmunology</i> , 2001, 112, 163-173.	1.1	34
23	Late-onset myasthenia gravis â€“ CTLA4 ^{low} genotype association and low-for-age thymic output of na ⁺ ve T cells. <i>Journal of Autoimmunity</i> , 2014, 52, 122-129.	3.0	29
24	Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups. <i>Journal of Clinical Immunology</i> , 2012, 32, 230-237.	2.0	21
25	Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of Myasthenia Gravis. <i>BMC Genomics</i> , 2008, 9, 481.	1.2	8
26	Expression of Muscle Proteins in Thymomas of Patients with Myasthenia Gravis. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 411-413.	1.8	5
27	Mapping of Helper Epitopes to HPA-1a in Neonatal Alloimmune Thrombocytopenia with T-Cell Clones. <i>Blood</i> , 2008, 112, 3040-3040.	0.6	4
28	New polymorphism of the human T-cell receptor AV28S1 gene segment. <i>Immunogenetics</i> , 1998, 48, 62-64.	1.2	3
29	Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis. <i>Neurology: Clinical Practice</i> , 2019, 9, 48-52.	0.8	2
30	Use of Peptide:HLA Class II Complexes to Study Specific T Cells in Autoimmune Myasthenia Gravis. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 339-342.	1.8	1
31	The perioperative management of thymectomy in myasthenia gravis: an overview. <i>British Journal of Neuroscience Nursing</i> , 2007, 3, 261-264.	0.1	1
32	The legacy of John Newsom-Davis (1932â€“2007). <i>Journal of Neuroimmunology</i> , 2008, 201-202, 1.	1.1	1